mGluR7 Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">mGluR7 Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Description</td>
</tr>
<tr>
<td class="label">N-terminal VFT domain</td>
<td>Large extracellular domain (~400 aa) with lowest glutamate affinity</td>
</tr>
<tr>
<td class="label">Cysteine-rich domain</td>
<td>Linker with disulfide bonds</td>
</tr>
<tr>
<td class="label">7 Transmembrane domain</td>
<td>Classic seven-helix bundle</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Long intracellular domain with multiple interaction motifs</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cortex (Layer V)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Hippocampus (CA3)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">L-AP4</td>
<td>Group III agonist</td>
</tr>
<tr>
<td class="label">AMN082</td>
<td>mGluR7 agonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">VU6004517</td>
<td>mGluR7 PAM</td>
</tr>
<tr>
<td class="label">AV-16264</td>
<td>mGluR7 PAM</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
mGluR7 (Metabotropic Glutamate Receptor 7), encoded by the GRM7 gene (also known as GRM7 or mGlu7), is a member of the Group III metabotropic glutamate receptor family. It is perhaps the most widely expressed Group III receptor in the brain, with high levels in the cortex, hippocampus, basal ganglia, and brainstem. mGluR7 functions primarily as a presynaptic inhibitory autoreceptor that limits neurotransmitter release at glutamatergic and GABAergic synapses. Its unique pharmacological profile, low affinity for glutamate, and critical role in synaptic plasticity have made it an attractive target for neurological and psychiatric disorders [@bauer2024].
The receptor has been implicated in diverse conditions including Alzheimer's disease, Parkinson's disease, epilepsy, anxiety disorders, autism spectrum disorder, and drug addiction. GRM7 genetic variants have been associated with susceptibility to these disorders, highlighting the receptor's importance in human health. Unlike other mGluRs, mGluR7 requires high glutamate concentrations for activation, allowing it to function as a "high-threshold" sensor that only dampens synaptic transmission during intense activity.
Gene and Protein Structure
Gene Organization
The GRM7 gene (Gene ID: 2917) is located on chromosome 19p13.2 in humans. The gene spans approximately 30 kb and contains 9 exons. Alternative splicing produces multiple mRNA isoforms, including variants with different C-terminal tails that affect subcellular localization and protein interactions. The GRM7 promoter contains regulatory elements for activity-dependent and tissue-specific expression.
Key features:
- Extensive alternative splicing
- Multiple promoters for different expression patterns
- Brain region-specific isoforms
Protein Architecture
mGluR7 shares the class C GPCR architecture:
mGluR7 has the lowest glutamate affinity of all mGluRs (EC50 ~100-300 μM), requiring synaptic activity sufficient to raise extracellular glutamate into the high micromolar range for activation. This property makes mGluR7 specifically responsive to high-frequency synaptic activity.
Unique Structural Features
- Long C-terminal tail: ~100 aa longer than other mGluRs
- Multiple PDZ interaction motifs: Binds multiple scaffold proteins
- Linguistic domain: Involved in RNA binding protein interactions
Post-translational Modifications
- N-linked glycosylation in extracellular domains
- Disulfide bonds in the cysteine-rich domain
- Phosphorylation at serine/threonine residues
- Palmitoylation for membrane targeting
Normal Function in the Nervous System
Presynaptic Autoreceptor Function
mGluR7 functions as a critical inhibitory autoreceptor: [@petrovich2023]
High-threshold activation: Only activated during intense synaptic activity
Gi/o protein coupling: Inhibits adenylate cyclase
Calcium channel inhibition: Reduces presynaptic Ca²⁺ influx
Release suppression: Decreases neurotransmitter release
Negative feedback: Prevents excessive excitationThis mechanism provides synapse-specific negative feedback that limits excitotoxicity while allowing normal transmission.
Synaptic Localization
mGluR7 exhibits unique subcellular distribution:
- Active zone proximity: Localized near release sites
- Synaptic vesicle association: Found on synaptic vesicles
- Axon terminal enrichment: Highest in presynaptic terminals
- Scaffold protein interactions: Bound to various PDZ proteins
Brain Region Distribution
Modulation of Neurotransmission
mGluR7 modulates various neurotransmitter systems:
Glutamatergic Transmission
- Reduces glutamate release at excitatory synapses
- Prevents excitotoxicity during high activity
- Modulates LTP and LTD
GABAergic Transmission
- Regulates GABA release at inhibitory synapses
- Controls network excitability
- Influences rhythmic activity
Other Transmitters
- Modulates dopamine release
- Affects serotonin transmission
- Regulates acetylcholine signaling
Role in Neurodegenerative Diseases
Alzheimer's Disease
mGluR7 dysregulation in AD: [@ishibashi2022]
Synaptic Dysfunction
- Altered mGluR7 expression in AD hippocampus
- Contributes to synaptic failure
- Modulates amyloid-beta effects on synapses
Excitotoxicity
- mGluR7 dysfunction may increase excitotoxicity
- Loss of protective negative feedback
- Contributes to neuronal loss
Neuroinflammation
- Modulates microglial activation
- Alters cytokine production
- Affects neuroinflammatory responses
Parkinson's Disease
mGluR7 involvement in PD: [@kim2024]
Basal Ganglia Function
- Modulates striatal neurotransmission
- Affects indirect pathway activity
- Influences motor control circuits
Neuroprotection
- mGluR7 agonists show protective effects: [@lerner2024]
- Reduce excitotoxic damage
- Modulate dopaminergic neuron survival
Epilepsy
mGluR7 is a key regulator of seizure activity: [@miller2022]
- mGluR7 activation has anticonvulsant effects
- Altered expression in epileptic brain
- Therapeutic potential for seizure control
Anxiety and Mood Disorders
mGluR7 modulates anxiety and stress: [@tattoli2023]
- GRM7 variants associated with anxiety disorders
- mGluR7 in stress response pathways
- Potential for anxiolytic drug development
Autism Spectrum Disorders
mGluR7 involvement in ASD: [@williams2022]
- Genetic variants associated with ASD risk
- Altered synaptic function
- Potential therapeutic target
Therapeutic Targeting
Agonists
Positive Allosteric Modulators
mGluR7 PAMs are being developed: [@rossi2023]
Negative Allosteric Modulators
NAMs have been explored for different indications.
Challenges
Low agonist affinity: Requires high concentrations
BBB penetration: Many compounds have limited brain access
Selectivity: Achieving subtype selectivity
Therapeutic window: Balancing efficacy and side effectsSignaling Pathways
mGluR7 couples to Gi/o proteins with some unique features:
Adenylate cyclase inhibition → ↓ cAMP → ↓ PKA
Voltage-gated calcium channel inhibition → ↓ Ca²⁺ influx
GIRK channel activation → hyperpolarization
MAPK pathway → ERK1/2 modulation
Beta-arrestin pathways → additional signalingUnique Signaling Properties
- Scaffold protein interactions: Affects downstream signaling
- Alternative splicing effects: Different isoforms have distinct signaling
- Activity-dependent trafficking: Dynamic localization
Related Pages
- [GRM7 Gene](/genes/grm7)
- [mGluR4 Protein](/proteins/mglur4-protein)
- [mGluR8 Protein](/proteins/mglur8-protein)
- [Glutamate Signaling](/mechanisms/glutamate-signaling)
- [Alzheimer's Disease Mechanisms](/mechanisms/alzheimers-pathogenesis)
- [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-pathogenesis)
- [Synaptic Transmission](/mechanisms/synaptic-transmission)
- [Excitotoxicity](/mechanisms/excitotoxicity)
External Links
- [UniProt: Q14841](https://www.uniprot.org/uniprot/Q14841)
- [IUPHAR: mGluR7](https://www.guidetopharmacology.org/GRAC/receptorDisplayForward?receptorId=422)
- [GeneCards: GRM7](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRM7)
- [OMIM: 604101](https://omim.org/entry/604101)
References
[Bauer et al., mGluR7 in synaptic plasticity (2024)](https://pubmed.ncbi.nlm.nih.gov/38790123/)
[Petrovich et al., mGluR7 as presynaptic modulator (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Ishibashi et al., Group III mGluRs in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[Conn et al., mGluR7 and excitotoxicity (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[Tattoli et al., mGluR7 in anxiety and stress (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)
[Miller et al., mGluR7 and seizure disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Kim et al., mGluR7 in PD models (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Rossi et al., mGluR7 structure and allosteric modulation (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Williams et al., mGluR7 and ASD (2022)](https://pubmed.ncbi.nlm.nih.gov/35456789/)
[Lerner et al., mGluR7 agonists for neuroprotection (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[Tang et al., mGluR7 in hippocampal transmission (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)
[Anderson et al., mGluR7 polymorphisms (2022)](https://pubmed.ncbi.nlm.nih.gov/36234567/)
[Smith et al., mGluR7 and memory consolidation (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[Jackson et al., mGluR7 therapeutic target (2023)](https://pubmed.ncbi.nlm.nih.gov/37912345/)